Back to results
US 7,888,072 B2Granted
Heparan sulfate glycosaminoglycan lyase and uses thereof
AssigneeMomenta Pharmaceuticals, Inc.
InventorJames Myette
Life of this patent
Estimating the term…
Abstract
The invention provides recombinant B. thetaiotaomicron GAG lyase polypeptides. The invention also provides nucleic acid molecules encoding such polypeptides, recombinant expression vectors containing B. thetaiotaomicron GAG lyase nucleic acid molecules, and host cells into which the expression vectors have been introduced. Characterization, diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
Claims8
A method of specifically cleaving heparin or heparan sulfate, comprising:
- selecting a B. thetaiotaomicron HSGAG lyase polypeptide II, or functional fragments thereof, that cleaves a heparin or heparin sulfate such that anti-Xa activity is maintained or increased and anti-IIa activity is reduced as compared to the anti-Xa activity and anti-IIa activity of the heparin or heparan sulfate cleaved with heparinase III from Flavobacterium heparinum, wherein the B. thetaiotaomicron HSGAG lyase II polypeptide, or functional fragment thereof, comprises
- a) an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:6;
- b) the amino acid sequence of SEQ ID NO:6, 8, or 10;
- and
- c) an amino acid sequence which differs by at least 1 amino acid but not more than 15 amino acids from the amino acid sequence of SEQ ID NO:6;
- and
- contacting the heparin or the heparin sulfate with the B. thetaiotaomicron HSGAG lyase polypeptide II, to thereby cleave the heparin or heparan sulfate.
4 more elements
Dependencies are inferred from the claim text.